Patrick James Bradley

Prof. Patrick James Bradley

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in British Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
PBPatrick James Bradley
Patrick James Bradley
MMMark McGurk
Mark McGurk

1 April 2003 in Current Opinion in Otolaryngology & Head and Neck Surgery
Verified
Journal Article
Closed access
PBPatrick James Bradley
Patrick James Bradley
NJNick S. Jones
Nick S. Jones
IRIain Robertson
Iain Robertson
Esthesioneuroblastoma is an uncommon malignant neoplasm of the nasal vault that in the past was considered benign or low-grade malignant. Surgical approaches in the main were transnasal, with a high recurrence rate and ultimate patient death. With the modern imaging of CT and MRI, should the patient be willing and fit enough, esthesioneuroblastoma currently should be approached using a craniofacial resection. Large tumors should be considered for preoperative chemotherapy and postoperative radiotherapy. Local tumor recurrence is not uncommon and is generally related to the attention to local anatomic dissection. Neck metastases, when they present, should be excised using a modified neck dissection. Distant metastases may present at any time during the course of the disease, generally within 36 months, and may respond to local radiotherapy or systemic chemotherapy. Five-year survival currently appears to be optimized by surgery followed by postoperative radiotherapy and is approximately 65%.

8 June 2023 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
AMAntti Mäkitie
Antti Mäkitie
RARasheed Alabi
Rasheed Alabi
SNSweet Ping Ng
Sweet Ping Ng
RTRobert P Takes
Robert P Takes
KRK Thomas Robbins
K Thomas Robbins
Alfio FerlitoAlfio Ferlito
Alfio Ferlito
Introduction Several studies have emphasized the potential of artificial intelligence (AI) and its subfields, such as machine learning (ML), as emerging and feasible approaches to optimize patient care in oncology. As a result, clinicians and decision-makers are faced with a plethora of reviews regarding the state of the art of applications of AI for head and neck cancer (HNC) management. This article provides an analysis of systematic reviews on the current status, and of the limitations of the application of AI/ML as adjunctive decision-making tools in HNC management. Methods Electronic databases (PubMed, Medline via Ovid, Scopus, and Web of Science) were searched from inception until November 30, 2022. The study selection, searching and screening processes, inclusion, and exclusion criteria followed the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. A risk of bias assessment was conducted using a tailored and modified version of the Assessment of Systematic Review (AMSTAR-2) tool and quality assessment using the Risk of Bias in Systematic Reviews (ROBIS) guidelines. Results Of the 137 search hits retrieved, 17 fulfilled the inclusion criteria. This analysis of systematic reviews revealed that the application of AI/ML as a decision aid in HNC management can be thematized as follows: (1) detection of precancerous and cancerous lesions within histopathologic slides; (2) prediction of the histopathologic nature of a given lesion from various sources of medical imaging; (3) prognostication; (4) extraction of pathological findings from imaging; and (5) different applications in radiation oncology. In addition, the challenges in implementation of AI/ML models for clinical evaluations include the lack of standardized methodological guidelines for the collection of clinical images, development of these models, reporting of their performance, external validation procedures, and regulatory frameworks. Conclusion At present, there is a paucity of evidence to suggest the adoption of these models in clinical practice due to the aforementioned limitations. Therefore, this manuscript highlights the need for development of standardized guidelines to facilitate the adoption and implementation of these models in the daily clinical practice. In addition, adequately powered, prospective, randomized controlled trials are urgently needed to further assess the potential of AI/ML models in real-world clinical settings for the management of HNC.

1 April 2011 in Current Opinion in Otolaryngology & Head and Neck Surgery
Verified
Journal Article
Closed access
PBPatrick James Bradley
Patrick James Bradley
PBPaula T Bradley
Paula T Bradley
KOKerry D Olsen
Kerry D Olsen
Parapharyngeal space (PPSp) tumours are uncommon and hence the 'generalist expertise' for diagnosis and treatment is limited. Recent improvements in radiology and cytopathology mean the likely diagnosis is more certain and hence the recommended surgical treatment can be more definitive. A wide spectrum of primary pathologies are reported to involve the PPSp; the majority (80%) are benign neoplasms. Radiological imaging, computed tomography (CT) and MRI, with diagnostic fine needle aspiration cytology (FNAC), have continued to increase preoperative diagnostic accuracy. Thus, it is easier to identify the patients whose external surgery may rarely require a mandibulotomy. Only highly selected cases can be safely excised via a transoral approach. All tumours of the PPSp require accurate diagnosis, using modern diagnostic imaging and FNAC. Surgery, in most cases, remains the treatment of choice. Many neurogenic tumours and paragangliomas can be observed in elderly patients. The optimum surgical approach for complete excision needs to be selected on an individual basis. Each patient must be adequately informed of the associated morbidity and possible complications, likelihood of cure and the risk of tumour recurrence - short and long term. Most tumours can be excised safely, and with low risk of recurrence and short hospitalization, with a cervical-parotid approach.

13 August 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
MQMiquel Quer
Miquel Quer
JHJuan C. Hernandez-Prera
Juan C. Hernandez-Prera
CSCarl E. Silver
Carl E. Silver
MCMaria Casasayas
Maria Casasayas
RSRicard Simo
Ricard Simo
Alfio FerlitoAlfio Ferlito
Alfio Ferlito
Purpose: To review the current options in the management of Warthin tumors (WTs) and to propose a working management protocol. Methods: A systematic literature search was conducted using PubMed and ScienceDirect database. A total of 141 publications were selected and have been included in this review. Publications were selected based on relevance, scientific evidence, and actuality. Results: The importance of parotid WTs is increasing due to its rising incidence in many countries, becoming the most frequently encountered benign parotid tumor in certain parts of the world. In the past, all WTs were treated with surgery, but because of their slow growth rate, often minimal clinical symptoms, and the advanced age of many patients, active observation has gradually become more widely used. In order to decide on active surveillance, the diagnosis of WT must be reliable, and clinical, imaging, and cytological data should be concordant. There are four clear indications for upfront surgery: uncertain diagnosis; cosmetic problems; clinical complaints, such as pain, ulceration, or recurrent infection; and the patient’s wish to have the tumor removed. In the remaining cases, surgery can be elective. Active surveillance is often suggested as the first approach, with surgery being considered if the tumor progresses and/or causes clinical complaints. The extent of surgery is another controversial topic, and the current trend is to minimize the resection using partial parotidectomies and extracapsular dissections when possible. Recently, non-surgical options such as microwave ablation, radiofrequency ablation, and ultrasound-guided ethanol sclerotherapy have been proposed for selected cases. Conclusions: The management of WT is gradually shifting from superficial or total parotidectomy to more conservative approaches, with more limited resections, and to active surveillance in an increasing number of patients. Additionally, non-surgical treatments are emerging, but their role needs to be defined in future studies.

30 January 2007 in ORL
Verified
Journal Article
Closed access
PBPatrick James Bradley
Patrick James Bradley
LMLisha McClelland
Lisha McClelland
DMDeepak Mehta
Deepak Mehta
Salivary gland epithelial neoplasms in children are rare. Clinicians of all disciplines need to have a high level of suspicion when a non-inflammatory single mass lesion presents in the parotid or submandibular glands. There is high likelihood of malignancy when such a mass presents. Surgery is the primary treatment of choice in the majority of cases, with the addition of adjuvant radiotherapy ± chemotherapy when the diagnosis is a high-grade tumour and/or when the malignancy presents as a large mass or is associated with local tissue invasion. Minor salivary gland neoplasms also present, the oral cavity is most frequent, with pleomorphic adenoma and mucoepidermoid carcinoma being most common, other malignant neoplasms have been reported in other sites.